Brokers Set Expectations for Clorox’s Q4 Earnings (NYSE:CLX)

The Clorox Company (NYSE:CLX) – Analysts at Zacks Research upped their Q4 2025 earnings estimates for shares of Clorox in a research note issued on Monday, May 19th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.23 per share for the quarter, up from their previous forecast of $2.14. The consensus estimate for Clorox’s current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox’s Q1 2026 earnings at $1.52 EPS, Q2 2026 earnings at $1.51 EPS, Q3 2026 earnings at $1.57 EPS, FY2026 earnings at $6.71 EPS, Q1 2027 earnings at $1.62 EPS, Q2 2027 earnings at $1.71 EPS and Q3 2027 earnings at $1.70 EPS.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). The firm had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.74 billion. Clorox had a return on equity of 316.87% and a net margin of 6.38%. The company’s revenue was down 8.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.71 EPS.

Several other analysts also recently weighed in on CLX. UBS Group dropped their target price on shares of Clorox from $176.00 to $154.00 and set a “neutral” rating on the stock in a research report on Thursday, April 17th. JPMorgan Chase & Co. dropped their target price on shares of Clorox from $151.00 to $144.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 6th. DA Davidson dropped their target price on shares of Clorox from $171.00 to $169.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Morgan Stanley dropped their target price on shares of Clorox from $165.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $150.00 price objective on shares of Clorox in a report on Thursday, January 30th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $151.23.

Clorox Stock Down 2.7%

NYSE:CLX opened at $131.90 on Wednesday. The company has a market cap of $16.26 billion, a PE ratio of 36.04, a P/E/G ratio of 2.62 and a beta of 0.60. Clorox has a twelve month low of $127.60 and a twelve month high of $171.37. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The company’s 50 day moving average is $140.26 and its two-hundred day moving average is $152.82.

Hedge Funds Weigh In On Clorox

Several hedge funds and other institutional investors have recently modified their holdings of CLX. Integral Investment Advisors Inc. raised its position in Clorox by 4.1% in the 4th quarter. Integral Investment Advisors Inc. now owns 1,718 shares of the company’s stock valued at $279,000 after purchasing an additional 67 shares during the last quarter. Sonora Investment Management Group LLC raised its position in Clorox by 2.5% in the 1st quarter. Sonora Investment Management Group LLC now owns 2,940 shares of the company’s stock valued at $433,000 after purchasing an additional 72 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Clorox by 0.6% in the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,266 shares of the company’s stock valued at $1,953,000 after purchasing an additional 73 shares during the last quarter. Horizon Investments LLC raised its position in Clorox by 4.4% in the 1st quarter. Horizon Investments LLC now owns 1,768 shares of the company’s stock valued at $258,000 after purchasing an additional 75 shares during the last quarter. Finally, Sfmg LLC raised its position in Clorox by 2.8% in the 1st quarter. Sfmg LLC now owns 2,780 shares of the company’s stock valued at $409,000 after purchasing an additional 76 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Clorox

In related news, Director Pierre R. Breber acquired 4,000 shares of the firm’s stock in a transaction on Wednesday, May 7th. The shares were acquired at an average cost of $136.57 per share, with a total value of $546,280.00. Following the completion of the acquisition, the director now directly owns 4,000 shares in the company, valued at approximately $546,280. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.57% of the company’s stock.

Clorox Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 9th. Shareholders of record on Wednesday, April 23rd were issued a dividend of $1.22 per share. This represents a $4.88 annualized dividend and a yield of 3.70%. The ex-dividend date was Wednesday, April 23rd. Clorox’s payout ratio is 87.61%.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.